Results 141 to 150 of about 785,489 (353)

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

Annals of Oncology, 2019
Background Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however, there is a lack of understanding of the characteristics of EGFR mutant lung tumors ...
K. Hastings, H.A. Yu, W. Wei, F. Sanchez-Vega, M. Deveaux, J. Choi, H. Rizvi, A. Lisberg, A. Truini, C. Lydon, Z. Liu, B. Henick, A. Wurtz, G. Cai, A. Plodkowski, N. Long, D. Halpenny, J. Killam, I. Oliva, N. Schultz, Gregory Riely, M. Arcila, M. Ladanyi, D. Zelterman, R. Herbst, S. Goldberg, M. Awad, E. Garon, S. Gettinger, M. Hellmann, K. Politi   +30 more
semanticscholar   +1 more source

The EGFR Polymorphism Increased the Risk of Hepatocellular Carcinoma Through the miR-3196-Dependent Approach in Chinese Han Population

Pharmacogenomics and Personalized Medicine, 2021
Li Zhang, Xiaoping Li, Jiang Lu, Yi Qian, Tao Qian, Xing Wu, Qinghua Xu Department of Hepatobiliary and Pancreatic Surgery, LiYang People’s Hospital, LiYang, 213300, Jiangsu, People’s Republic of ChinaCorrespondence: Qinghua Xu; Xing ...
Zhang L, Li X, Lu J, Qian Y, Qian T, Wu X, Xu Q   +6 more
doaj  

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab [PDF]

, 2015
Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone.
Abouelkhair, KM, Cascinu, S, Del Prete, M, Faloppi, L, Giampieri, R, Ibrahim, EM, Loretelli, C, Mandolesi, A, Maristella, B, Scarpelli, M, Scartozzi, M   +10 more
core   +3 more sources

Serum soluble mediator signatures of lupus nephritis: histological features and response to treatment

Arthritis Care &Research, Accepted Article.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histological features and treatment response.
Andrea Fava, Catriona A. Wagner, Carla J. Guthridge, Susan Macwana, Wade DeJager, Melissa E. Munroe, Peter Izmirly, H. Michael Belmont, Betty Diamond, Anne Davidson, Paul J. Utz, Michael H Weisman, Philip M Carlucci, Maria Dall'Era, Kenneth Kalunian, Chaim Putterman, Jennifer Anolik, Jennifer L Barnas, David Wofsy, Diane Kamen, Richard A Furie, Deepak A Rao, the Accelerating Medicines Partnership (AMP) RA/SLE Network, Michelle Petri, Joel M. Guthridge, Jill Buyon, Judith A. James   +26 more
wiley   +1 more source

Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation [PDF]

, 2015
Bhumsuk Keam, Soo Jin Lee, Tae Min Kim, Jin Chul Paeng, Se‐Hoon Lee, Dong‐Wan Kim, Yoon Kyung Jeon, Doo Hyun Chung, Keon Wook Kang, June-Key Chung, Dae Seog Heo   +10 more
openalex   +1 more source

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Proceedings of the National Academy of Sciences of the United States of America, 2008
Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug ...
C. Yun, Kristen E. Mengwasser, A. Toms, M. S. Woo, H. Greulich, Kwok-kin Wong, M. Meyerson, M. Eck   +7 more
semanticscholar   +1 more source

Biophysical evidence for intrinsic disorder in the C-terminal tails of the epidermal growth factor receptor (EGFR) and HER3 receptor tyrosine kinases [PDF]

, 2016
The epidermal growth factor receptor (EGFR)/ErbB family of receptor tyrosine kinases includes oncogenes important in the progression of breast and other cancers, and they are targets for many drug development strategies.
Bose, Ron, Keppel, Theodore R, Monsey, John, Murray, Elisa M, Sarpong, Kwabena, Zhu, Jian   +5 more
core   +2 more sources

Response to allopurinol and febuxostat according to the fractional excretion of urate in men with gout

Arthritis Care &Research, Accepted Article.
Background Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate‐lowering response to allopurinol. We investigated whether the fractional excretion of urate (FEUA) also modulates this response and relates to oxypurinol concentrations. We further evaluated its potential influence
Pascal Richette, Anouk Walter‐Petrich, Quang Dinh Nguyen, Matthieu Resche‐Rigon, Quang Huy Dinh Nguyen, Minh Duc Do, Thao Phuong Mai, Tuan Duc Nguyen, Fernando Perez‐Ruiz, Emmanuel Letavernier, Tristan Pascart, Augustin Latourte, Hang Korng Ea, Thomas Bardin   +13 more
wiley   +1 more source

The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies [PDF]

, 2019
Hsiang-Ling Ho, Hua‐Lin Kao, Yi-Chen Yeh, Teh‐Ying Chou   +3 more
openalex   +1 more source

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Clinical Cancer Research, 2016
Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC) harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) experience disease progression during treatment due to brain metastases. Despite
P. Ballard, J. Yates, Zhenfan Yang, Dong-Wan Kim, J. Yang, M. Cantarini, K. Pickup, Angela Jordan, Mike Hickey, Matthew Grist, Matthew R. Box, P. Johnström, K. Varnäs, J. Malmquist, K. Thress, P. Jänne, D. Cross   +16 more
semanticscholar   +1 more source